5:02 PM ET
8-K
Investor Presentation
Praxis Precision Medicines Investor Presentation
Praxis Precision Medicines hosted an Investor Day in New York City to detail its commercial strategy and launch plans for ulixacaltamide in essential tremor and relutrigine in DEEs. The company also provided an expanded pipeline update, including plans to initiate studies for ulixacaltamide in Parkinson’s disease and autism spectrum disorder in 2027.